In conclusion, based on the novel findings of PCOS etiology in genetic, epigenetic, and cortical brain responses, these effective therapeutic targets, such as SAM, IL-22 supplementation, and fezolinetant, will lead to a new area in the future management of PCOS. The gene discussed is IL22; the disease is polycystic ovary syndrome.